NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

ATLnsider,

The big consideration isn’t the cost of the treatment per se, I believe it’s the additive up front cost to SOC that needs to be addressed by those who know this will quickly be ramping up into other indications. The need to control costs when it does will likely impact the perceived relative importance for chemo and radiation in all of these indications. Temodar will likely not be SOC for unmethylated GBM and other indications where it provides no benefit and in older patients where lower dose or elimination of it led to better results with DCVax-L. NICE will want MHRA to adjust SOC according to actual benefit as soon as possible once L usage ramp up begins in earnest. Patients will also experience a better quality of life with these adjustments so I expect a balancing act begin to play out between the old SOC and new SOC being established once L is approved as this will help mitigate the impact of additional up front costs created by treatment with L. Best wishes.